Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.

Subjects

Subjects :

Adult
Antimetabolites, Antineoplastic therapeutic use
Antineoplastic Agents pharmacology
Benzamides
Combined Modality Therapy
Cytarabine therapeutic use
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl antagonists & inhibitors
Fusion Proteins, bcr-abl genetics
Granulocyte Colony-Stimulating Factor pharmacology
Humans
Imatinib Mesylate
Interferons therapeutic use
Lenograstim
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Leukemia, Myeloid, Chronic-Phase drug therapy
Leukemia, Myeloid, Chronic-Phase genetics
Male
Piperazines pharmacology
Pyrimidines pharmacology
Recombinant Proteins pharmacology
Remission Induction
Antineoplastic Agents therapeutic use
Hematopoietic Stem Cell Mobilization
Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery
Leukemia, Myeloid, Chronic-Phase surgery
Peripheral Blood Stem Cell Transplantation
Piperazines therapeutic use
Pyrimidines therapeutic use
Transplantation, Autologous

Details

Language :

English

ISSN :

1592-8721

Volume :

90 Suppl

Database :

MEDLINE

Journal :

Haematologica

Publication Type :

Academic Journal

Accession number :

16266927